Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5918964 | 0.81 | MAOB (0.50) | PPARGL3MBTL1SMN1; SMN2RXRARXRB | |
| SCHEMBL31294997 | 0.81 | PAX8 (0.47) | HDAC3HDAC1HDAC2NCOR2PPARG | |
| SCHEMBL9342265 | 0.80 | RXRA (0.51) | PPARGSMN1; SMN2RXRARXRBRXRG | |
| SCHEMBL2936587 | 0.78 | PPARA (0.46) | HDAC3HDAC1HDAC2NCOR2PPARG | |
| SCHEMBL7813239 | 0.75 | PPARG (0.36) | PPARGPPARAL3MBTL1SMN1; SMN2RXRA | |
| SCHEMBL2937645 | 0.75 | GPR119 (0.47) | HDAC3HDAC1HDAC2NCOR2PPARG | |
| SCHEMBL9347235 | 0.74 | ESR1 (0.43) | PPARGMEN1KMT2AALDH1A1 | |
| SCHEMBL14558985 | 0.74 | GLS (0.48) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL1314001 | 0.74 | AGXT (0.42) | L3MBTL1SMN1; SMN2MAOBALDH1A1HTT | |
| SCHEMBL2935519 | 0.73 | HDAC1 (0.40) | HDAC3HDAC1HDAC2NCOR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| EP-1601384-B1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | GE HEALTHCARE AS (NO) | 2010-09-22 | — | — | EP | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| EP-1601384-A1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | Amersham Health AS (NO) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080492-A1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | AMERSHAM HEALTH AS (NO) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | DOHH, VGF, HNRNPH3 | HDAC3 188/4885HDAC1 368/4885HDAC2 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.